Filter By Category
Archives
Share on -
ACREOZAST
Generic Name: ACREOZAST
ABSTRACT -
Acreozast is an investigational leukotriene receptor antagonist under development for inflammatory respiratory and allergic conditions. It targets cysteinyl leukotriene receptors to reduce airway inflammation and bronchoconstriction. Research is ongoing for its potential use in asthma and allergic rhinitis management.
DOSAGE -
Acreozast is currently an investigational drug. Dosage is determined by clinical trial protocol. Oral administration is anticipated based on its pharmacological class. No established clinical dosing outside of trials.
SIDE EFFECTS –
Reported or potential side effects may include:
- Headache
- Upper respiratory tract infections
- Fatigue
- Dizziness
- Gastrointestinal disturbances
- Elevated liver enzymes
ALLRGIC REACTIONS–
(These symptoms may indicate an allergic reaction to the drug.)
- Skin rash
- Urticaria
- Angioedema
- Hypersensitivity reactions
- Difficulty breathing
DRUG INTERACTIONS–
- CYP3A4 inducers and inhibitors
- Other leukotriene receptor antagonists
- Bronchodilators
- Corticosteroids
PREAUTIONS–
- Safety in pregnancy and breastfeeding not established.
- Monitor liver enzymes during treatment.
- Do not discontinue other asthma medications abruptly.
- Inform physician of all concurrent medications.
- Monitor for neuropsychiatric symptoms.
WARNINGS –
- Not a rescue medication for acute asthma attacks.
- Neuropsychiatric events including mood changes reported with related drugs.
- Long-term safety under evaluation.
- Keep out of reach of children.
- Report worsening of asthma symptoms immediately.
Share on -
. Developed by